| Description | This product is a human neutralizing antibody that binds to human norovirus capsid protein (HuNoV Capsid). It showed broad blockade toward tested GII.4 strains and neutralized the pandemic GII.P16-GII.4 Sydney strain. This product has been tested using Neutralization assay. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | HuNoV (GII.P16 and GII.4 strain) |
| Immunogen | Bivalent GII.4c + GI.1 VLP vaccine |
| Epitope | Capsid P Domain |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; Neut |
| Application Notes | The results of Neutralization assay demonstrated that the IC₅₀ of the mAb to GII.P16-GII.4 Sydney virus is 5.5 ng/mL. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | HuNoV Capsid |
| Alternative Name | Human norovirus capsid |
| Research Area | Infectious Disease |
| Related Disease | Acute gastroenteritis |
